<?xml version="1.0" encoding="UTF-8"?>
<ref id="B94-biomedicines-08-00060">
 <label>94.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>He</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Geng</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>An</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Ye</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Yan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Yin</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy</article-title>
  <source>Eur. J. Pharmacol.</source>
  <year>2017</year>
  <volume>802</volume>
  <fpage>85</fpage>
  <lpage>92</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.02.042</pub-id>
  <pub-id pub-id-type="pmid">28246027</pub-id>
 </element-citation>
</ref>
